Caris Life Sciences, a next-generation AI TechBio company and precision medicine pioneer, entered into an agreement with Moderna in support of Moderna’s oncology and novel therapeutics initiatives.

Through the multi-year agreement, Moderna will leverage Caris’ vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna’s oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.

“Partnering with Caris Life Sciences will support Moderna’s oncology portfolio with clinico-genomics data from Caris’ industry-leading and comprehensive suite of integrated precision medicine capabilities,” said Praveen Aanur, vice president, oncology therapeutic area head of Moderna.

“We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives,” said David Spetzler, president of Caris Life Sciences. “The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna’s innovative medicines.”